Finance

Lists
GETI-B:STO
Getinge publ AB
249,90 SEK
+1,42%
(+3,50) 1D
5 ოქტ, 17:29:37 GMT+2  ·   SEK
All symbols
SymbolPriceChange% Change
Generating top insights for GETI-B...
Open
246,40 SEK
High
250,90 SEK
Low
246,00 SEK
Mkt. cap
63,51 მლრდ.
Avg. vol.
570,26 ათ.
Volume
482,43 ათ.
Dividend
1,90%
Quarterly dividend
1,19 SEK
Ex-dividend date
22 აპრ. 2026
P/E ratio
25,45
52-wk high
251,40 SEK
52-wk low
175,90 SEK
EPS
9,82 SEK
Shares outstanding
254,15 მლნ.
No. of employees
12 ათ.
Open
246,40 SEK
High
250,90 SEK
Low
246,00 SEK
Mkt. cap
63,51 მლრდ.
Avg. vol.
570,26 ათ.
Volume
482,43 ათ.
Dividend
1,90%
Quarterly dividend
1,19 SEK
Ex-dividend date
22 აპრ. 2026
P/E ratio
25,45
52-wk high
251,40 SEK
52-wk low
175,90 SEK
EPS
9,82 SEK
Shares outstanding
254,15 მლნ.
No. of employees
12 ათ.
News stories
From web sources and news partners
AD HOC NEWS
AD HOC NEWS
·
7 საათის წინ
Analysts lift fair value for Getinge stock to SEK 251.70
Profile
Getinge AB is a publicly traded Swedish medical technology company. The company produces and distributes medical products and equipment for the healthcare and life sciences industries. The company is divided into three business areas: Life Science, Acute Care Therapies, and Surgical Workflows. The group employs approximately 12,000 people worldwide. The CEO of the company is Mattias Perjos, and the chairman of the board is Johan Malmquist. With a sales share of around 40%, the United States is by far the most important market for the company due to significantly higher prices and margins there. China and various Western European countries follow. Wikipedia
About Getinge publ AB
CEOMattias Perjos
Employees11,8 ათ.
Founded1904
Headquarters-
SectorMedical device
Previous reportsAll values in SEK
Loading Previous Earnings...
Revenue
Net income
All values in SEK
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
8,23 მლრდ.
10,19 მლრდ.
7,44 მლრდ.
8,38 მლრდ.
Cost of goods sold
4,41 მლრდ.
5,38 მლრდ.
3,84 მლრდ.
3,96 მლრდ.
Cost of revenue
4,41 მლრდ.
5,38 მლრდ.
3,84 მლრდ.
3,96 მლრდ.
Research and development expenses
307,00 მლნ.
484,00 მლნ.
328,00 მლნ.
358,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,51 მლრდ.
2,76 მლრდ.
2,55 მლრდ.
2,71 მლრდ.
Operating expense
2,83 მლრდ.
3,10 მლრდ.
2,87 მლრდ.
3,06 მლრდ.
Total operating expenses
7,24 მლრდ.
8,49 მლრდ.
6,70 მლრდ.
7,03 მლრდ.
Operating income
985,00 მლნ.
1,70 მლრდ.
738,00 მლნ.
1,35 მლრდ.
Other non operating income
2,00 მლნ.
-105,00 მლნ.
-1,00 მლნ.
-
EBT including unusual items
790,00 მლნ.
1,21 მლრდ.
572,00 მლნ.
1,15 მლრდ.
EBT excluding unusual items
824,00 მლნ.
1,26 მლრდ.
602,00 მლნ.
1,22 მლრდ.
Income tax expense
214,00 მლნ.
338,00 მლნ.
170,00 მლნ.
312,00 მლნ.
Effective tax rate
27,09%
28,03%
29,72%
27,11%
Other operating expenses
17,00 მლნ.
-136,00 მლნ.
-12,00 მლნ.
-
Net income
566,00 მლნ.
868,00 მლნ.
401,00 მლნ.
841,00 მლნ.
Net profit margin
6,88%
8,52%
5,39%
10,03%
Earnings per share
2,42
4,45
1,80
3,59
Interest and investment income
-
73,00 მლნ.
-
-
Interest expense
-163,00 მლნ.
-103,00 მლნ.
-135,00 მლნ.
-133,00 მლნ.
Net interest expenses
-163,00 მლნ.
-30,00 მლნ.
-135,00 მლნ.
-133,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
1,27 მლრდ.
1,97 მლრდ.
1,01 მლრდ.
1,63 მლრდ.
Gain or loss from assets sale
-
40,00 მლნ.
-
-
AI content may include mistakes. Learn more
Google აპები